Elisabetta Bianchi,Paul E. Carrington,Qiaolin Deng,Ravi Nargund,Federica Orvieto,Anandan Palani,Antonello Pessi,Thomas Joseph Tucker,Chengwei Wu
申请号：
US15519565
公开号：
US20170360893A1
申请日:
2015.10.22
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity
